BiotechTube
ExoLytics

ExoLytics

San Diego, United States· Est.
exolytics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

ExoLytics is a private, pre-clinical stage biotech startup targeting the global antimicrobial resistance (AMR) crisis. The company's innovative approach centers on engineering endolysins—enzymes that rapidly break down bacterial cell walls—as a new class of targeted, narrow-spectrum therapeutics intended to be alternatives to traditional antibiotics. Operating in a high-need, high-opportunity market, ExoLytics aims to develop disruptive solutions for drug-resistant infections, though it faces significant scientific, regulatory, and commercial challenges typical of an early-stage venture. The company appears to be pre-revenue and in the foundational research and platform development phase.

Infectious Diseases

Technology Platform

Engineered endolysin enzymes derived from bacteriophages, designed to precisely target and lyse drug-resistant bacterial pathogens.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The global crisis of antimicrobial resistance (AMR) creates a massive, high-priority unmet medical need and a corresponding market opportunity for novel therapies.
Increasing government incentives and funding mechanisms (e.g., CARB-X, potential PASTEUR Act) are improving the economic landscape for antibiotic development.
Endolysins offer a potentially differentiated profile with rapid, targeted killing and a low propensity for resistance development.

Risk Factors

The company faces high scientific risk in demonstrating that its engineered endolysin platform is effective, deliverable, and safe in humans.
The regulatory pathway for a novel biologic antimicrobial is complex and uncertain.
The antimicrobial market is commercially challenging due to stewardship, pricing pressures, and the need for companion diagnostics to guide targeted therapy use.

Competitive Landscape

ExoLytics competes in the growing field of non-traditional antimicrobials, which includes companies developing phage therapies (e.g., Adaptive Phage Therapeutics), lysins (e.g., ContraFect, Lysovant), and other novel modalities. Several competitors are more advanced in clinical development. The company also competes indirectly with developers of next-generation small molecule antibiotics and monoclonal antibodies for infections.

More companies in United States →